Natick biotech receives preclinical proof of concept for tumor treatment
Photo | Courtesy of Google
Affyimmune Therapeutics, Inc. is headquartered on Strathmore Road in Natick.
Avenge Bio, Inc., a Natick biotechnology company, announced on Monday that a paper has been published on the efficacy of its LOCOcyte immunotherapy platform, which is used to administer treatments to solid tumors.
The paper, authored by a fleet of researchers based at Rice University in Texas and published in the journal Clinical Cancer Research, specifically deals with the platform’s use for treating pleural malignant mesothelioma.
The paper provides Avenge with peer-reviewed preclinical proof of concept of the treatment, as the company heads into a clinical trial later this year. The U.S. Food and Drug Administration has cleared the technology for an investigational new drug application for treatment of ovarian cancer.
The Rice University paper is called “Activation of adaptive and innate immune cells via localized Interleukin-2 cytokine factories eradicates mesothelioma tumors.”
“Pleural mesothelioma is a devastating malignancy that has traditionally defeated standard therapies,” said Dr. Bryan Burt, chief of the Division of Thoracic Surgery at Baylor College of Medicine in Texas, in a statement. “Local delivery of a therapeutic can reduce toxicity by confining the immunostimulatory effects to local tumor microenvironment, highlighting a strong rationale for developing Avenge's LOCOcyte platform.”
Avenge has an exclusive license from Rice University for the technology, per a press release.
WBJ Web Partners
Most Recent
Most Recent
0 Comments